Emerald Acquisition’s Aratana Therapeutics, Inc. PETX Stock Holding History

Emerald Acquisition’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$477K	Buy	+51,009	New	+$424K	﹤0.01%	2456

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's PETX Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Aratana Therapeutics, Inc. (PETX) in Q3 2016: 51,009 shares worth $477K. The stake represents ﹤0.01% of the portfolio and ranks #2456 among its holdings.

128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

Emerald Acquisition held 51,009 shares of Aratana Therapeutics, Inc. worth $477K as of Q3 2016.
Aratana Therapeutics, Inc. was a new Emerald Acquisition position in Q3 2016.
Aratana Therapeutics, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2456 holding.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.